Antibiotic Resistance of Helicobacter pylori: Data from Central Asia

2024

Full text Open access: Green Metadata (CSL-JSON)
DOI 10.20944/preprints202409.1357.v1
Data confidence 70 medium
How this score is calculated

It is built from checkable properties of the record itself: whether the article has a DOI, how many independent sources confirmed its data, whether the required fields are filled in, and how recent the latest confirmation is. Disagreement between sources and a missing identifier lower it. A value of 80 or above means the record was published without further checking; 60 to 79 means it is published at reduced confidence, with a manual check advisable. A record verified by an editor by hand is never pushed below 90 by a recalculation. This scores our data about the article, not the article itself.

Abstract

Helicobacter pylori (H. pylori) is a global health concern, particularly in regions with a high incidence of stomach cancer. The effective eradication of this bacteria is essential for the prevention and treatment of related gastrointestinal disorders. However, antibiotic resistance has emerged as a significant challenge to effective treatment. This review examines antibiotic resistance among H. pylori populations in Central Asia, a region with limited data on this topic. We critically analyze the available literature, exploring the mechanisms behind resistance and highlighting implications for clinical practice and future research. Despite the lack of studies in the region, data suggest alarming levels of resistance to two common antibiotics, clarithromycin and metronidazole. These results underscore the need for enhanced surveillance and personalized treatment strategies to combat H. pylori infections and reduce the risk of stomach cancer in Central Asian populations.